- April 20, 2017
- Posted by:
- Category: FundingSMEs.com
Lyndra Inc. has raised $23 million in Series A funding.
Founded in 2015, Lyndra Inc. ’s technology is the first ultra-long acting, sustained release oral dosage form. Lyndra’s system enables linear drug release of small molecules and peptides for 7 days or more from each orally administered capsule.
The company will utilize the capital raised to further the development of its lead candidate program and increase manufacturing capabilities.
|Founder / CEO||Amy Schulman|
|Investors||Suffolk Equity Partners|